EDIT · CIK 0001650664 · operating
Based in Cambridge, Massachusetts, Editas Medicine is a clinical-stage biotechnology company developing genomic medicines using CRISPR gene editing technology. The company's therapeutic pipeline targets a range of serious diseases through its proprietary genome editing platform. Notable programs include a research collaboration with Juno Therapeutics focused on alpha-beta T-cell experimental medicines for solid and liquid tumors.
The company operates primarily as a drug development entity without significant commercial-stage revenue at this time. Editas maintains its research and development operations in the United States, with a workforce of 246 full-time employees as of the most recent reporting period. The company was incorporated in Delaware in 2013, originally founded as Gengine, Inc. before adopting its current name that same year.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.88 | $-2.88 | -42.6% | |
| 2023 | $-2.02 | $-2.02 | +37.1% | |
| 2022 | $-3.21 | $-3.21 | -13.4% | |
| 2021 | $-2.83 | $-2.85 | -183.0% | |
| 2020 | $-1.00 | $-1.00 | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-05 | 0001650664-25-000022 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0001650664-24-000008 | SEC ↗ |
| 2022-12-31 | 2023-02-22 | 0001558370-23-001764 | SEC ↗ |
| 2021-12-31 | 2022-02-24 | 0001558370-22-001950 | SEC ↗ |
| 2020-12-31 | 2021-02-26 | 0001558370-21-001915 | SEC ↗ |
| 2019-12-31 | 2020-02-26 | 0001558370-20-001476 | SEC ↗ |
| 2018-12-31 | 2019-03-01 | 0001558370-19-001364 | SEC ↗ |
| 2017-12-31 | 2018-03-08 | 0001558370-18-001721 | SEC ↗ |
| 2016-12-31 | 2017-03-03 | 0001558370-17-001340 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001558370-16-004455 | SEC ↗ |